- Previous Close
65.10 - Open
64.91 - Bid 64.70 x 1200
- Ask 65.30 x 900
- Day's Range
64.56 - 65.77 - 52 Week Range
58.93 - 96.12 - Volume
10,880,710 - Avg. Volume
6,767,350 - Market Cap (intraday)
39.246B - Beta (5Y Monthly) 1.13
- PE Ratio (TTM)
25.65 - EPS (TTM)
2.54 - Earnings Date Oct 23, 2024 - Oct 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
76.58
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
www.edwards.comRecent News: EW
View MorePerformance Overview: EW
Trailing total returns as of 10/2/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EW
View MoreValuation Measures
Market Cap
39.25B
Enterprise Value
37.95B
Trailing P/E
25.65
Forward P/E
25.45
PEG Ratio (5yr expected)
3.44
Price/Sales (ttm)
6.37
Price/Book (mrq)
5.28
Enterprise Value/Revenue
6.12
Enterprise Value/EBITDA
21.83
Financial Highlights
Profitability and Income Statement
Profit Margin
23.74%
Return on Assets (ttm)
12.28%
Return on Equity (ttm)
22.02%
Revenue (ttm)
6.2B
Net Income Avi to Common (ttm)
1.54B
Diluted EPS (ttm)
2.54
Balance Sheet and Cash Flow
Total Cash (mrq)
1.99B
Total Debt/Equity (mrq)
9.23%
Levered Free Cash Flow (ttm)
820.77M
Research Analysis: EW
View MoreCompany Insights: EW
EW does not have Company Insights
Research Reports: EW
View MoreLowering target price to $52.00
EDWARDS LIFESCIENCES CORP has an Investment Rating of SELL; a target price of $52.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $61.00
EDWARDS LIFESCIENCES CORP has an Investment Rating of SELL; a target price of $61.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetLowering target price to $60.00
EDWARDS LIFESCIENCES CORP has an Investment Rating of SELL; a target price of $60.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetWhat does Argus have to say about EW?
EDWARDS LIFESCIENCES CORP has an Investment Rating of HOLD; a target price of $73.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice Target